Reports Q4 revenue $184.5M, consensus $574.18M. "In 2022, our team exceeded our strategic goals, achieving record HEPLISAV-B revenue, advancing our clinical pipeline and delivering orders of CpG 1018 adjuvant for the equivalent of hundreds of millions of COVID-19 vaccine doses," said CEO Ryan Spencer. "Following a year of successful execution on our strategy, we are excited for 2023 and look forward to continuing our trend of significant and sustainable annual HEPLISAV-B revenue growth and overall advancement of our business focused on protecting patients worldwide from infectious diseases."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on DVAX:
- Dynavax Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Full Year 2023 Financial Guidance
- Dynavax reports results from Phase 1 trial of shingles vaccine Z-1018
- Dynavax Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Financial Highlights and Phase 1 Shingles Topline Results
- Dynavax reports Q4 preliminary HEPLISAV-B net product revenue $35M
